Merck will make a second go at convincing advisers to the Food and Drug Administration to approve the cholesterol medicine Mevacor as an over-the-counter medicine.
A meeting before an FDA advisory panel is scheduled for Dec. 13. The panel of experts will weigh new data Merck hopes will satisfy concerns the drug is safe enough for consumers to take without a prescription.
The FDA rejected a similar request from the Whitehouse Station-based drugmaker in 2005.
Mevacor, which once generated annual sales of $1 billion, has lost market share to lower-priced generics. Last year, the drug brought in $20 million in sales for Merck.
Hat tip: Susan Todd
Insider's view: Remember, McNeil market Zocor OTC in the UK http://www.mcneilhealth.co.uk/zocor/.
Sales are, Insider gathers, uninspiring!
No comments:
Post a Comment